Publication

Vitamin K antagonists versus heparin for the treatment of splanchnic vein thrombosis in the ISTH registry: Results of 12-month follow-up and a propensity score analysis

Riva, N., Ageno, W., Schulman, S., Bang, S. M., Teresa Sartori, M., Grandone, E., Beyer-Westendorf, J., Barillari, G., Di Minno, M. N. D., Duce, R., Malato, A., Santoro, R., Poli, D., Verhamme, P., Martinelli, I., Kamphuisen, P., Alatri, A., Oh, D., D'Amico, E. A., Rezende, S. M., Becattini, C., Bucherini, E. & Dentali, F., 1-Nov-2014, In : Thrombosis Research. 134, p. 34-35 2 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Riva, N., Ageno, W., Schulman, S., Bang, S. M., Teresa Sartori, M., Grandone, E., ... Dentali, F. (2014). Vitamin K antagonists versus heparin for the treatment of splanchnic vein thrombosis in the ISTH registry: Results of 12-month follow-up and a propensity score analysis. Thrombosis Research, 134, 34-35.

Author

Riva, N. ; Ageno, W. ; Schulman, S. ; Bang, S.M. ; Teresa Sartori, M. ; Grandone, E. ; Beyer-Westendorf, J. ; Barillari, G. ; Di Minno, M.N.D. ; Duce, R. ; Malato, A. ; Santoro, R. ; Poli, D. ; Verhamme, P. ; Martinelli, I. ; Kamphuisen, P. ; Alatri, A. ; Oh, D. ; D'Amico, E.A. ; Rezende, S.M. ; Becattini, C. ; Bucherini, E. ; Dentali, F. / Vitamin K antagonists versus heparin for the treatment of splanchnic vein thrombosis in the ISTH registry: Results of 12-month follow-up and a propensity score analysis. In: Thrombosis Research. 2014 ; Vol. 134. pp. 34-35.

Harvard

Riva, N, Ageno, W, Schulman, S, Bang, SM, Teresa Sartori, M, Grandone, E, Beyer-Westendorf, J, Barillari, G, Di Minno, MND, Duce, R, Malato, A, Santoro, R, Poli, D, Verhamme, P, Martinelli, I, Kamphuisen, P, Alatri, A, Oh, D, D'Amico, EA, Rezende, SM, Becattini, C, Bucherini, E & Dentali, F 2014, 'Vitamin K antagonists versus heparin for the treatment of splanchnic vein thrombosis in the ISTH registry: Results of 12-month follow-up and a propensity score analysis', Thrombosis Research, vol. 134, pp. 34-35.

Standard

Vitamin K antagonists versus heparin for the treatment of splanchnic vein thrombosis in the ISTH registry: Results of 12-month follow-up and a propensity score analysis. / Riva, N.; Ageno, W.; Schulman, S.; Bang, S.M.; Teresa Sartori, M.; Grandone, E.; Beyer-Westendorf, J.; Barillari, G.; Di Minno, M.N.D.; Duce, R.; Malato, A.; Santoro, R.; Poli, D.; Verhamme, P.; Martinelli, I.; Kamphuisen, P.; Alatri, A.; Oh, D.; D'Amico, E.A.; Rezende, S.M.; Becattini, C.; Bucherini, E.; Dentali, F.

In: Thrombosis Research, Vol. 134, 01.11.2014, p. 34-35.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Riva N, Ageno W, Schulman S, Bang SM, Teresa Sartori M, Grandone E et al. Vitamin K antagonists versus heparin for the treatment of splanchnic vein thrombosis in the ISTH registry: Results of 12-month follow-up and a propensity score analysis. Thrombosis Research. 2014 Nov 1;134:34-35.


BibTeX

@article{2c9364f5f6034835b29ecb693b3d029b,
title = "Vitamin K antagonists versus heparin for the treatment of splanchnic vein thrombosis in the ISTH registry: Results of 12-month follow-up and a propensity score analysis",
abstract = "Introduction: Splanchnic vein thrombosis [SVT] is a challenging disease, because of the concurrent increased risk of bleeding and potentially lifethreatening complications. We aimed to explore the actual management of SVT in a large prospective cohort and to report clinical outcomes during follow-up. Methods: Consecutive SVT patients were enrolled in a multicenter international registry, from 2008 to 2012. Clinical outcomes (major bleeding; vascular events, defined as venous or arterial thrombosis; mortality) were collected. A propensity score [PS], created from baseline characteristics of patients receiving the two main treatments (different dosages of parenteral anticoagulants vs vitamin K antagonists [VKAs]), was used to estimate the effect of therapeutic strategies. We here report the results of the 12-month follow-up. Results: 613 patients were enrolled; mean age 53.1±14.8 years; 62.6{\%} males. Initially, 143 patients were not anticoagulated; 175 received parenteral anticoagulants only (mean duration 6.28±4.21 months) and 295 started VKAs (9.67±3.53 months). Major bleeding occurred in 25 patients, 16 on treatment (4.53/100 patientyears [pt-y]) and 9 off treatment (5.45/100 pt-y); vascular events in 47 patients, 27 and 20 (7.93/100 pt-y vs 11.85/100 pt-y); death in 79 patients, 44 and 35 (12.35/100 pt-y vs 20.30/100 pt-y). Solid cancer, ascites, anemia and thrombocytopenia were inversely associated with the prescription of VKAs in a binary logistic regression. Using PS based on these variables, we matched 102 patients treated with VKAs with 102 patients treated with parenteral anticoagulants. Major bleeding occurred in 5.88{\%} vs 0.98{\%} for VKAs and heparin, respectively; vascular events in 2.94{\%} vs 8.82{\%}; mortality in 5.88{\%} vs 18.63{\%}. Conclusions: In our cohort of SVT patients, the incidence of vascular and bleeding events at 1-year follow-up was relevant. Although the PS matching did not allow for a complete balance of heterogeneity, in designated patients VKA treatment appeared to be sufficiently safe.",
keywords = "heparin, antivitamin K, anticoagulant agent, vein thrombosis, register, follow up, propensity score, society, hemostasis, thrombosis, human, patient, bleeding, mortality, solid, death, artery thrombosis, neoplasm, logistic regression analysis, prescription, thrombocytopenia, anemia, ascites, male, risk",
author = "N. Riva and W. Ageno and S. Schulman and S.M. Bang and {Teresa Sartori}, M. and E. Grandone and J. Beyer-Westendorf and G. Barillari and {Di Minno}, M.N.D. and R. Duce and A. Malato and R. Santoro and D. Poli and P. Verhamme and I. Martinelli and P. Kamphuisen and A. Alatri and D. Oh and E.A. D'Amico and S.M. Rezende and C. Becattini and E. Bucherini and F. Dentali",
year = "2014",
month = "11",
day = "1",
language = "English",
volume = "134",
pages = "34--35",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "PERGAMON-ELSEVIER SCIENCE LTD",

}

RIS

TY - JOUR

T1 - Vitamin K antagonists versus heparin for the treatment of splanchnic vein thrombosis in the ISTH registry: Results of 12-month follow-up and a propensity score analysis

AU - Riva, N.

AU - Ageno, W.

AU - Schulman, S.

AU - Bang, S.M.

AU - Teresa Sartori, M.

AU - Grandone, E.

AU - Beyer-Westendorf, J.

AU - Barillari, G.

AU - Di Minno, M.N.D.

AU - Duce, R.

AU - Malato, A.

AU - Santoro, R.

AU - Poli, D.

AU - Verhamme, P.

AU - Martinelli, I.

AU - Kamphuisen, P.

AU - Alatri, A.

AU - Oh, D.

AU - D'Amico, E.A.

AU - Rezende, S.M.

AU - Becattini, C.

AU - Bucherini, E.

AU - Dentali, F.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Introduction: Splanchnic vein thrombosis [SVT] is a challenging disease, because of the concurrent increased risk of bleeding and potentially lifethreatening complications. We aimed to explore the actual management of SVT in a large prospective cohort and to report clinical outcomes during follow-up. Methods: Consecutive SVT patients were enrolled in a multicenter international registry, from 2008 to 2012. Clinical outcomes (major bleeding; vascular events, defined as venous or arterial thrombosis; mortality) were collected. A propensity score [PS], created from baseline characteristics of patients receiving the two main treatments (different dosages of parenteral anticoagulants vs vitamin K antagonists [VKAs]), was used to estimate the effect of therapeutic strategies. We here report the results of the 12-month follow-up. Results: 613 patients were enrolled; mean age 53.1±14.8 years; 62.6% males. Initially, 143 patients were not anticoagulated; 175 received parenteral anticoagulants only (mean duration 6.28±4.21 months) and 295 started VKAs (9.67±3.53 months). Major bleeding occurred in 25 patients, 16 on treatment (4.53/100 patientyears [pt-y]) and 9 off treatment (5.45/100 pt-y); vascular events in 47 patients, 27 and 20 (7.93/100 pt-y vs 11.85/100 pt-y); death in 79 patients, 44 and 35 (12.35/100 pt-y vs 20.30/100 pt-y). Solid cancer, ascites, anemia and thrombocytopenia were inversely associated with the prescription of VKAs in a binary logistic regression. Using PS based on these variables, we matched 102 patients treated with VKAs with 102 patients treated with parenteral anticoagulants. Major bleeding occurred in 5.88% vs 0.98% for VKAs and heparin, respectively; vascular events in 2.94% vs 8.82%; mortality in 5.88% vs 18.63%. Conclusions: In our cohort of SVT patients, the incidence of vascular and bleeding events at 1-year follow-up was relevant. Although the PS matching did not allow for a complete balance of heterogeneity, in designated patients VKA treatment appeared to be sufficiently safe.

AB - Introduction: Splanchnic vein thrombosis [SVT] is a challenging disease, because of the concurrent increased risk of bleeding and potentially lifethreatening complications. We aimed to explore the actual management of SVT in a large prospective cohort and to report clinical outcomes during follow-up. Methods: Consecutive SVT patients were enrolled in a multicenter international registry, from 2008 to 2012. Clinical outcomes (major bleeding; vascular events, defined as venous or arterial thrombosis; mortality) were collected. A propensity score [PS], created from baseline characteristics of patients receiving the two main treatments (different dosages of parenteral anticoagulants vs vitamin K antagonists [VKAs]), was used to estimate the effect of therapeutic strategies. We here report the results of the 12-month follow-up. Results: 613 patients were enrolled; mean age 53.1±14.8 years; 62.6% males. Initially, 143 patients were not anticoagulated; 175 received parenteral anticoagulants only (mean duration 6.28±4.21 months) and 295 started VKAs (9.67±3.53 months). Major bleeding occurred in 25 patients, 16 on treatment (4.53/100 patientyears [pt-y]) and 9 off treatment (5.45/100 pt-y); vascular events in 47 patients, 27 and 20 (7.93/100 pt-y vs 11.85/100 pt-y); death in 79 patients, 44 and 35 (12.35/100 pt-y vs 20.30/100 pt-y). Solid cancer, ascites, anemia and thrombocytopenia were inversely associated with the prescription of VKAs in a binary logistic regression. Using PS based on these variables, we matched 102 patients treated with VKAs with 102 patients treated with parenteral anticoagulants. Major bleeding occurred in 5.88% vs 0.98% for VKAs and heparin, respectively; vascular events in 2.94% vs 8.82%; mortality in 5.88% vs 18.63%. Conclusions: In our cohort of SVT patients, the incidence of vascular and bleeding events at 1-year follow-up was relevant. Although the PS matching did not allow for a complete balance of heterogeneity, in designated patients VKA treatment appeared to be sufficiently safe.

KW - heparin

KW - antivitamin K

KW - anticoagulant agent

KW - vein thrombosis

KW - register

KW - follow up

KW - propensity score

KW - society

KW - hemostasis

KW - thrombosis

KW - human

KW - patient

KW - bleeding

KW - mortality

KW - solid

KW - death

KW - artery thrombosis

KW - neoplasm

KW - logistic regression analysis

KW - prescription

KW - thrombocytopenia

KW - anemia

KW - ascites

KW - male

KW - risk

M3 - Article

VL - 134

SP - 34

EP - 35

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -

ID: 17430195